Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers
Introduction
Official Title
Official Title
An adaptive, phase I, randomized, placebo-controlled, sponsor-unblinded, multiple ascending dose study to investigate the safety, tolerability and pharmacokinetics of intravenous CSL112 in healthy volunteers
Objectives
Objectives
- To measure the biomarkers of cholesterol movement following a single and multiple infusions of CSL-112 in healthy subjects.[1]
- To evaluate role of CSL-112 in decreasing cholesterol-loaded plaques that contribute to cardiovascular disease.[1]
Sponsor
Sponsor
CSL Limited
Timeline
Timeline
| Timeline | |
| Start Date | January 2011 |
| End Date | June 2011 |
| Status | Completed |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT01281774.
Study Description
Study Description
| Study Description | |
| Study Type | Interventional |
| Study Phase | Phase 1 |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Safety study |
| Interventional Model | Parallel assignment |
| Masking | Double blind |
| Study Details | |
| Primary Purpose | Treatment |
| Condition | Healthy |
| Intervention | Biological: CSL112 (reconstituted high density lipoprotein) Biological: Placebo (normal saline) |
| Study Arms | Multiple ascending intravenous doses of CSL112 Placebo |
| Population Size | 36 |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT01281774.
Eligibility Criteria
Eligibility Criteria
Inclusion Criteria
- Healthy individual
- Age: 18-55 year old
- Weight ≥ 5 kg
- BMI between 18-42 kg/m2
Exclusion Criteria
- Clinically significant medical condition or disease
- Abnormal lab test result
- History of alcohol or other substance abuse
Outcomes
Outcomes
Primary Outcomes
Safety and tolerability defined as rate of clinically-associated adverse events that occur within 14 days of CSL112 infusion.[1]
Secondary Outcomes
Evaluation of lipoprotein pharmacokinetics during a time frame of 10 days following CSL112 infusion and measurement of plasma levels of lipoprotein.[1]
Publications
Publications
Results
- Infusions of CSL-112 caused immediate and profound elevation in all the biomarkers of cholesterol transport, including preBeta1-HDL and global cholesterol efflux as measured by activity of ATP-binding cassette transporter (ABCA1) cells.[1]
- Serum preBeta1-HDL elevation was up to 20-fold.[1]
- The infusion of CSL112 caused a dose-dependent increase of all biomarkers. Levels were consistent in magnitude and time course following the first and last infusions.[1]
- Serum preBeta1-HDL and cholesterol efflux capacity peaked after infusion and returned to baseline at 24 hour while there was a 72 hour sustained response for serum HDL following its peak at 24-48 hours after infusion.[1]
- Multiple infusions of CSL112 cause a greater efflux of cholesterol from tissues to HDL when compared with a single infusion.[1]
- There were no observed changes in the baseline of other lipoproteins.[1]
Conclusion
Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.[1]
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]